Trial
NCT00003512
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Burzynski Research Institute
Collaborators
—
Condition
Waldenstrom Macroglobulinemia
Intervention
Antineoplaston therapy (Atengenal + Astugenal)
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-05